Shenzhen Bioeasy Biotechnology Co., Ltd. (SHE:300942)
China · Delayed Price · Currency is CNY 9.80
-0.01 (-0.10%)
Feb 13, 2026, 3:04 PM CST
SHE:300942 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 249.41 | 221.82 | 243.57 | 676.32 | 583.14 | 236.1 |
Other Revenue | 2.43 | 2.43 | 10.54 | 10.58 | 14.4 | 22.35 |
| 251.83 | 224.25 | 254.11 | 686.9 | 597.54 | 258.46 | |
Revenue Growth (YoY) | 1.93% | -11.75% | -63.01% | 14.95% | 131.20% | 8.06% |
Cost of Revenue | 80.82 | 68.15 | 157.92 | 345.01 | 171.38 | 76.73 |
Gross Profit | 171.02 | 156.1 | 96.19 | 341.89 | 426.16 | 181.73 |
Selling, General & Admin | 101.02 | 95.23 | 151.18 | 151.19 | 100.05 | 72.5 |
Research & Development | 42.47 | 40.45 | 53.14 | 111.42 | 72.43 | 38.89 |
Other Operating Expenses | 8.59 | -3.09 | 3.52 | 2.51 | 3.16 | 1.71 |
Operating Expenses | 155.61 | 140.73 | 210.66 | 269.13 | 178.05 | 115.4 |
Operating Income | 15.4 | 15.38 | -114.47 | 72.76 | 248.1 | 66.33 |
Interest Expense | -26.26 | -18.67 | -10.63 | -4.08 | -2.38 | -0.37 |
Interest & Investment Income | 9.52 | 8.33 | 7.56 | 6.24 | 6.6 | 9.2 |
Currency Exchange Gain (Loss) | 2.65 | 2.65 | 6.03 | 9.23 | -4.14 | -10.49 |
Other Non Operating Income (Expenses) | 4.63 | 0.06 | -0.88 | -0.22 | -0.67 | -0.43 |
EBT Excluding Unusual Items | 5.94 | 7.75 | -112.39 | 83.93 | 247.51 | 64.24 |
Gain (Loss) on Sale of Investments | -1.73 | -3.98 | -54.08 | - | 5.21 | - |
Gain (Loss) on Sale of Assets | 11.96 | 2.28 | 2.81 | 1.43 | - | - |
Asset Writedown | -1.12 | -1.16 | -26.15 | -1.95 | -0 | -0.01 |
Other Unusual Items | 16.79 | 14.67 | 12.01 | 11.47 | 15.32 | 9.72 |
Pretax Income | 31.96 | 19.69 | -177.8 | 94.89 | 268.04 | 73.94 |
Income Tax Expense | -0.48 | 3.07 | 7.19 | 12.22 | 31.57 | 8.49 |
Earnings From Continuing Operations | 32.44 | 16.62 | -184.98 | 82.66 | 236.47 | 65.45 |
Minority Interest in Earnings | -1.2 | 0.5 | 0.08 | 0.3 | 0.04 | -0 |
Net Income | 31.24 | 17.12 | -184.91 | 82.97 | 236.51 | 65.45 |
Net Income to Common | 31.24 | 17.12 | -184.91 | 82.97 | 236.51 | 65.45 |
Net Income Growth | - | - | - | -64.92% | 261.38% | -29.10% |
Shares Outstanding (Basic) | 428 | 428 | 402 | 395 | 394 | 364 |
Shares Outstanding (Diluted) | 428 | 428 | 402 | 395 | 394 | 364 |
Shares Change (YoY) | 6.20% | 6.45% | 1.75% | 0.23% | 8.42% | 2.41% |
EPS (Basic) | 0.07 | 0.04 | -0.46 | 0.21 | 0.60 | 0.18 |
EPS (Diluted) | 0.07 | 0.04 | -0.46 | 0.21 | 0.60 | 0.18 |
EPS Growth | - | - | - | -65.00% | 233.33% | -30.77% |
Free Cash Flow | -72.88 | -139.85 | -165.89 | -24.29 | 175.92 | -19.04 |
Free Cash Flow Per Share | -0.17 | -0.33 | -0.41 | -0.06 | 0.45 | -0.05 |
Dividend Per Share | 0.017 | 0.017 | - | 0.021 | 0.249 | 0.045 |
Dividend Growth | - | - | - | -91.49% | 453.33% | - |
Gross Margin | 67.91% | 69.61% | 37.85% | 49.77% | 71.32% | 70.31% |
Operating Margin | 6.12% | 6.86% | -45.05% | 10.59% | 41.52% | 25.66% |
Profit Margin | 12.41% | 7.63% | -72.77% | 12.08% | 39.58% | 25.32% |
Free Cash Flow Margin | -28.94% | -62.36% | -65.29% | -3.54% | 29.44% | -7.37% |
EBITDA | 26.77 | 28.69 | -98.56 | 84.22 | 257.12 | 71.84 |
EBITDA Margin | 10.63% | 12.79% | -38.79% | 12.26% | 43.03% | 27.80% |
D&A For EBITDA | 11.37 | 13.31 | 15.91 | 11.46 | 9.01 | 5.52 |
EBIT | 15.4 | 15.38 | -114.47 | 72.76 | 248.1 | 66.33 |
EBIT Margin | 6.12% | 6.86% | -45.05% | 10.59% | 41.52% | 25.66% |
Effective Tax Rate | - | 15.59% | - | 12.88% | 11.78% | 11.49% |
Revenue as Reported | 251.83 | 224.25 | 254.11 | 686.9 | 597.54 | 258.46 |
Advertising Expenses | - | 0.13 | 0.96 | - | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.